Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495801 | 0.84 | CYP19A1 (0.45) | CYP19A1GRIA1ARALPL | |
| SCHEMBL4492290 | 0.84 | CHRNB4 (0.42) | GRIA1ARALPLMEN1KMT2A | |
| SCHEMBL4485924 | 0.84 | CYP19A1 (0.45) | CYP19A1GRIA1ARALPL | |
| SCHEMBL4484219 | 0.84 | CYP19A1 (0.45) | CYP19A1HTR2AHTR2CGRIA1AR | |
| SCHEMBL4489627 | 0.84 | CYP19A1 (0.45) | CYP19A1HTR2AHTR2CGRIA1AR | |
| SCHEMBL4498044 | 0.84 | ALPL (0.46) | CYP19A1HTR2AHTR2CHTR2BGRIA1 | |
| SCHEMBL13595228 | 0.81 | HTR2C (0.64) | HTR2AHTR2CHTR2B | |
| SCHEMBL4474599 | 0.81 | HPGD (0.40) | GRIA1ARMEN1KMT2A | |
| SCHEMBL4489951 | 0.81 | HTR2A (0.46) | HTR2AHTR2CHTR2BGRIA1AR | |
| SCHEMBL4484222 | 0.81 | KMT2A (0.46) | CYP19A1HTR2AHTR2CHTR2BGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| WO-2010150840-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2010-12-29 | — | — | WO | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | CYP19A1 216/4885HTR2A 2058/4885HTR2C 1209/4885 |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | CYP19A1 397/4885HTR2A 1634/4885HTR2C 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.